Viewing Study NCT06110195


Ignite Creation Date: 2025-12-24 @ 1:15 PM
Ignite Modification Date: 2025-12-30 @ 5:02 PM
Study NCT ID: NCT06110195
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-08
First Post: 2023-10-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Sponsor: University of Chicago
Organization:

Study Overview

Official Title: A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to determine the best safe dose of xevinapant that can be given in combination with chemotherapy and radiation in patients with head and neck cancer. Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After the best safe dose is found during escalation, an additional group of participants will be enrolled at that dose to learn more about the treatment combination (dose expansion).

The main question\[s\] it aims to answer are:

* what is the maximum safe dose that can be given
* what dose should be used in subsequent (phase 2) trials

Participants will receive xevinapant in combination with paclitaxel and carboplatin chemotherapy and radiation. Treatment will be given in 3-week cycles for 3 cycles.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: